Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd. (CMMB), a clinical-stage biotech firm, reported a net loss of $9.0 million for FY 2025 ending December 31, 2025, an improvement from $13.9 million in 2024 and $24.2 million in 2023, driven by reduced research and development expenses of $5.8 million (down 49% YoY from $11.3 million) following Phase 2 trial completion. General and administrative expenses rose slightly to $3.7 million (up 9% YoY). Total operating expenses were $9.6 million. Financing income netted $572K. Balance sheet shows total assets of $13.8 million, with cash and equivalents at $7.6 million, current assets $13.4 million, liabilities $1.5 million, and equity $12.3 million. Cash burn from operations was $11.1 million, offset by $5.4 million from investing (short-term deposit decrease) and $7.2 million from financing (share issuances), yielding $1.4 million cash increase. Shares outstanding: 575 million (issued), weighted average 510 million. Basic/diluted loss per share: $0.018. Cash runway extends to Q1 2027; additional funding needed for Phase 3 PSC trial.

Key Takeaways